SCHEMBL190274

SCHEMBL190274

Cc1cc(Nc2nc3ccccc3nc2NS(=O)(=O)c2cccc(NC(=O)CN(C)C)c2)ccc1F

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CG P48736 4/20 0.58
MAPT P10636 7/20 0.53
KDM4E B2RXH2 5/20 0.53
MEN1 O00255 6/20 0.52
KMT2A Q03164 6/20 0.52
POLB P06746 2/20 0.48
GFER P55789 1/20 0.48
CCNT1 O60563 1/20 0.48
CCNE1 P24864 1/20 0.48
CDK2 P24941 1/20 0.48
CDK9 P50750 1/20 0.48
LMNA P02545 3/20 0.47
SMN1; SMN2 Q16637 3/20 0.47
HPGD P15428 2/20 0.47
GAA P10253 2/20 0.47
GLA P06280 1/20 0.47
MAPK1 P28482 1/20 0.47
ALDH1A1 P00352 2/20 0.47
TTR P02766 1/20 0.46
CTNNB1 P35222 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL189356 0.89 PIK3CG (0.61) PIK3CGMAPTKDM4EMEN1KMT2A
SCHEMBL189772 0.89 PIK3CG (0.61) PIK3CGMAPTKDM4EMEN1KMT2A
SCHEMBL190022 0.89 PIK3CG (0.62) PIK3CGMAPTKDM4EMEN1KMT2A
SCHEMBL12364316 0.88 PIK3CG (0.66) PIK3CGMAPTKDM4EMEN1KMT2A
SCHEMBL189222 0.88 PIK3CG (0.61) PIK3CGMAPTKDM4EMEN1KMT2A
SCHEMBL189918 0.88 PIK3CG (0.61) PIK3CGMAPTKDM4EMEN1KMT2A
SCHEMBL189812 0.87 PIK3CG (0.63) PIK3CGMAPTKDM4EMEN1KMT2A
SCHEMBL188486 0.84 PIK3CG (0.73) PIK3CGMAPTKDM4EMEN1KMT2A
SCHEMBL189527 0.84 PIK3CG (0.73) PIK3CGMAPTMEN1KMT2APOLB
SCHEMBL188763 0.84 PIK3CG (0.57) PIK3CGMAPTKDM4EMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140100215-A1 Methods of Using PI3K and MEK Modulators EXELIXIS, INC. (US) 2014-04-10 US disclosed
US-8642584-B2 Method of using PI3K and MEK modulators EXELIXIS, INC. (US) 2014-02-04 US disclosed
US-8642584-B2 Method of using PI3K and MEK modulators EXELIXIS, INC. (US) 2014-02-04 US disclosed
US-20120302545-A1 Method of Using PI3K and MEK Modulators EXELIXIS, INC. (US) 2012-11-29 US disclosed
EP-2056829-B9 USING PI3K AND MEK MODULATORS IN TREATMENTS OF CANCER EXELIXIS INC (US) 2012-09-26 EP disclosed
EP-2056829-B1 USING PI3K AND MEK MODULATORS IN TREATMENTS OF CANCER EXELIXIS INC (US) 2012-01-04 EP disclosed
US-20100075947-A1 Methods of Using PI3K and MEK Modulators EXELIXIS, INC. (US) 2010-03-25 US disclosed
US-20100075947-A1 Methods of Using PI3K and MEK Modulators EXELIXIS, INC. (US) 2010-03-25 US disclosed
US-20100075947-A1 Methods of Using PI3K and MEK Modulators EXELIXIS, INC. (US) 2010-03-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100075947-A1 Methods of Using PI3K and MEK Modulators PIK3CA, PIK3CD, PIK3R1 PIK3CG 5/4885MAPT 4580/4885KDM4E 761/4885
US-20140100215-A1 Methods of Using PI3K and MEK Modulators PIK3CA, PIK3CD, PIK3R1 PIK3CG 5/4885MAPT 4580/4885KDM4E 761/4885
US-20120302545-A1 Method of Using PI3K and MEK Modulators PIK3CA, PIK3CD, PIK3R1 PIK3CG 6/4885MAPT 4606/4885KDM4E 729/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.